Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17793568 | 0.83 | SLC6A4 (0.50) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26326160 | 0.74 | SIGMAR1 (0.41) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL17793469 | 0.73 | SLC6A4 (0.49) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL19630908 | 0.73 | SLC6A4 (0.40) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL17793537 | 0.72 | SLC6A4 (0.50) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL17793470 | 0.70 | SLC6A4 (0.52) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL19630693 | 0.70 | SLC6A4 (0.65) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26326213 | 0.69 | SLC6A4 (0.39) | SLC6A4OPRM1OPRK1 | |
| SCHEMBL17793543 | 0.69 | SLC6A4 (0.63) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26324763 | 0.69 | SLC6A4 (0.41) | SLC6A4SIGMAR1CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | SLC6A4 305/4885SIGMAR1 14/4885CHRNB2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.